Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Böger
Rainer H
RH
Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. boeger@uke.uni-hamburg.de
Vallance
Patrick
P
Cooke
John P
JP
D001120:Arginine / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000378:metabolism* / Q000494:pharmacology*; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D020138:Hyperhomocysteinemia / Q000378:metabolism / Q000503:physiopathology; D006949:Hyperlipidemias / Q000378:metabolism / Q000503:physiopathology; D019001:Nitric Oxide Synthase / Q000187:drug effects / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D004791:Enzyme Inhibitors; C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase